Moreover, compared with other GLP-1 RAs, subcutaneous semaglutide (1 mg) and oral semaglutide (14 mg) administration yielded an improved reduction in body weight (WMD: 3.72 kg, 95% CI: 4.16 to 3.28, and WMD: 2.03 kg, 95% CI: 2.91 to 1.15, respectively)
Learn which option offers the best results and how they work in your weight loss journey
You can read the full article atYou can read the full article at Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial Due to increased obesity and inactivity rates, type 2 diabetes (T2D) is a complex, multifaceted disease with a rising prevalence rate
injection of 50% glucose (Sigma-Aldrich) solution at a dose of 2 g/kg body weight was administered to mice